SCHEMBL6313118

SCHEMBL6313118

COC(OC)c1cccc(NC(=O)CCC(=O)OC(C)(C)C)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
KDM4E B2RXH2 1/20 0.46
PTPRC P08575 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
CASR P41180 1/20 0.43
LMNA P02545 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CTSL P07711 1/20 0.42
PTPN13 Q12923 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
HDAC8 Q9BY41 1/20 0.41
TP53 P04637 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28527020 0.80 HDAC8 (0.57) MEN1KMT2APTPRCLMNACA1
SCHEMBL2655145 0.78 MEN1 (0.46) MEN1KMT2APTPRCCA1CA2
SCHEMBL21689945 0.77 LMNA (0.48) MEN1KMT2AKDM4ELMNAMAPT
SCHEMBL29730990 0.77 LMNA (0.48) MEN1KMT2AKDM4ELMNAMAPT
SCHEMBL21643478 0.74 TSHR (0.53) KMT2ACYP2C19CASRLMNA
SCHEMBL21643479 0.74 TSHR (0.53) KMT2ACYP2C19CASRLMNA
SCHEMBL29803337 0.74 TSHR (0.53) KMT2ACYP2C19CASRLMNA
SCHEMBL26814989 0.74 HPGD (0.56) MEN1KMT2AGAAMAPTHDAC8
SCHEMBL21643432 0.74 EPHX2 (0.49) RXFP1
SCHEMBL21643452 0.74 TSHR (0.52) CYP2C19CASRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014810-A1 Use of substituted 2 phenylbenzimidazoles as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014810-A1 Use of substituted 2 phenylbenzimidazoles as medicaments GLP1R, GIPR, GCGR MEN1 733/4885KMT2A 2473/4885KDM4E 2371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.